Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vimentin35-71Cit64 + calcitriol
- Development stage
- Preclinical
- Lead developer
- Dendright
- Modality
- Small Molecules, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
vimentin35-71Cit64 + calcitriol is an antigen-specific immunotherapy (ASI) liposomal formulation developed by the University of Queensland and its spin-off Dendright. It consists of liposomes (formulated with semi-synthetic phospholipids POPC and POPG) co-encapsulating the citrullinated autoantigen peptide vimentin35-71Cit64 and the NF-kB inhibitor calcitriol (1,25-dihydroxycholecalciferol). The therapy is designed to restore immune tolerance in patients with rheumatoid arthritis (RA). Following subcutaneous administration, the liposomes target antigen-presenting cells (APCs) in draining lymph nodes, where calcitriol inhibits NF-kB to promote a tolerogenic phenotype, and the vimentin peptide is presented to CD4+ T cells to induce regulatory T cells (Tregs) and suppress pro-inflammatory autoimmune responses.
- Other names
- vimentin35-71Cit64 + calcitriol liposomesvimentin35-71Cit64 and calcitriolvimentin-35-71Cit64 and calcitriolvimentin 35-71Cit64 and calcitriolvimentin35-71Cit64 and calcitriol liposomesvimentin-35-71Cit64 and calcitriol liposomesvimentin 35-71Cit64 and calcitriol liposomes
02
Targets
MHC II (Major histocompatibility complex class II receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on vimentin35-71Cit64 + calcitriol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vimentin35-71Cit64 + calcitriol.